INDACATEROL/GLYCOPYRRONIUM/ MOMETASONE (Enerzair Breezhaler)

Clinical Indication

Maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Comments

Not yet reviewed

Date of classification

February 2021

Review date

February 2021

Black

Drugs not recommended for use in the Leicestershire Health Community because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.

All new drugs will be black until they have been through the appropriate approval process - then they will appear as a specific entry.